• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Researchers Uses AI to Predict Dementia Risk from Eye Tests

by Jasmine Pennic 01/22/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– A new research project led by the University of Edinburgh is harnessing the power of artificial intelligence (AI) and routine eye tests to predict an individual’s risk of developing dementia. The NeurEYE team has amassed nearly a million eye scans from opticians across Scotland, creating the world’s largest dataset of its kind.

– By analyzing this vast dataset with AI and machine learning, researchers aim to identify patterns in eye scans that could indicate an increased risk of dementia. This innovative approach could revolutionize early detection and pave the way for more timely interventions and treatment strategies.

The Eye as a Window to the Brain

The connection between eye health and brain health is well-established. The blood vessels and neural pathways in the retina and brain are closely linked, offering valuable insights into neurological conditions like dementia.

“The eye can tell us far more than we thought possible,” says Professor Baljean Dhillon, Professor of Clinical Ophthalmology at the University of Edinburgh and NeurEYE co-lead. “Unlike the brain, we can see the retina with simple, inexpensive equipment found in every high street optician.”

The NeurEYE project is supported by NEURii, a global collaboration between Eisai, Gates Ventures, the University of Edinburgh, LifeArc, and Health Data Research UK. This partnership aims to translate innovative digital health projects into real-world solutions for neurodegenerative conditions.

AI-Powered Analysis for Early Detection

The NeurEYE team will use AI and machine learning to analyze the anonymized eye scan data, linking it to patient information such as demographics, treatment history, and pre-existing conditions. This analysis will help identify patterns and markers that could indicate an increased risk of dementia.

This AI-powered approach has the potential to transform dementia diagnosis and care by:

  • Enabling early detection: Identifying individuals at risk before symptoms appear, allowing for timely interventions and support.
  • Accelerating treatment development: Identifying individuals suitable for clinical trials and monitoring treatment responses more effectively.
  • Improving patient outcomes: Facilitating earlier diagnosis and personalized treatment plans, potentially slowing disease progression and improving quality of life.

The Importance of Ethical AI and Data Security

The NeurEYE team emphasizes the importance of ethical AI development and data security. The project has obtained permission to use the data from the Public Benefit and Privacy Panel for Health and Social Care, ensuring that patient privacy is protected. The data will be securely stored in the Scottish National Safe Haven, a platform for the safe and ethical use of NHS data.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |